Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.62 |
| ▸ | HPGD | P15428 | 5/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.51 |
| ▸ | MEN1 | O00255 | 7/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | HRH1 | P35367 | 3/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5922185 | 0.80 | ALDH1A1 (0.41) | ALDH1A1HPGDKDM4EKMT2AMEN1 | |
| SCHEMBL11961442 | 0.78 | KMT2A (0.54) | ALDH1A1HPGDKDM4EKMT2AMEN1 | |
| SCHEMBL3749553 | 0.77 | ALDH1A1 (1.00) | ALDH1A1HPGDKDM4EKMT2AMEN1 | |
| SCHEMBL11557945 | 0.73 | HPGD (0.62) | ALDH1A1HPGDKDM4EKMT2AMEN1 | |
| SCHEMBL563323 | 0.73 | ALDH1A1 (0.47) | ALDH1A1HPGDKDM4EKMT2AMEN1 | |
| SCHEMBL6714107 | 0.72 | ALDH1A1 (0.66) | ALDH1A1HPGDKDM4EKMT2AMEN1 | |
| SCHEMBL5658125 | 0.70 | ALDH1A1 (0.67) | ALDH1A1HPGDKDM4EKMT2AMEN1 | |
| SCHEMBL5922017 | 0.70 | ALDH1A1 (0.53) | ALDH1A1HPGDKDM4EKMT2AMEN1 | |
| SCHEMBL5922102 | 0.70 | ALDH1A1 (0.53) | ALDH1A1HPGDKDM4EKMT2AMEN1 | |
| SCHEMBL14003274 | 0.69 | ALDH1A1 (0.72) | ALDH1A1HPGDKDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404729-B2 | Heterocyclic tetracyclic tetrahydrofuran derivatives | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-26 | — | — | US | disclosed |
| US-8404729-B2 | Heterocyclic tetracyclic tetrahydrofuran derivatives | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-26 | — | — | US | disclosed |
| EP-1846415-B1 | HETEROCYCLIC TETRACYCLIC TETRAHYDROFURAN DERIVATIVES AS 5HT2 INHIBITORS IN THE TREATMENT OF CNS DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-01 | — | — | EP | disclosed |
| US-20110144094-A1 | HETEROCYCLIC TETRACYCLIC TETRAHYDROFURAN DERIVATIVES | CID-NUNEZ JOSE MARIA | 2011-06-16 | — | — | US | disclosed |
| US-20110144094-A1 | HETEROCYCLIC TETRACYCLIC TETRAHYDROFURAN DERIVATIVES | CID-NUNEZ JOSE MARIA | 2011-06-16 | — | — | US | disclosed |
| US-7915249-B2 | serotonin 5-HT2A, 5-HT2C and dopamin D2 receptors antagonist, and norepinephrine reuptake inhibitor; antidepressant, anxiolytic agent; psychosis, schizophrenia, bipolar and sexual disorders, obesity | JANSSEN PHARMACEUTICAL NV (BE) | 2011-03-29 | — | — | US | disclosed |
| US-7915249-B2 | serotonin 5-HT2A, 5-HT2C and dopamin D2 receptors antagonist, and norepinephrine reuptake inhibitor; antidepressant, anxiolytic agent; psychosis, schizophrenia, bipolar and sexual disorders, obesity | JANSSEN PHARMACEUTICAL NV (BE) | 2011-03-29 | — | — | US | disclosed |
| US-20080108599-A1 | Heterocyclic Tetracyclic Tetrahydrofuran Derivatives As 5Ht2 Inhibitors In The Treatment Of Cns Disorders | JANSSEN-CILAG S.A. (ES) | 2008-05-08 | — | — | US | disclosed |
| US-20080108599-A1 | Heterocyclic Tetracyclic Tetrahydrofuran Derivatives As 5Ht2 Inhibitors In The Treatment Of Cns Disorders | JANSSEN-CILAG S.A. (ES) | 2008-05-08 | — | — | US | disclosed |
| EP-1846415-A1 | HETEROCYCLIC TETRACYCLIC TETRAHYDROFURAN DERIVATIVES AS 5HT2 INHIBITORS IN THE TREATMENT OF CNS DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006079637-A1 | HETEROCYCLIC TETRACYCLIC TETRAHYDROFURAN DERIVATIVES AS 5HT2 INHIBITORS IN THE TREATMENT OF CNS DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-03 | — | — | WO | disclosed |
| US-4171366-A | 1-Naphthothienylalkyl-1H-imidazoles | CIBA-GEIGY CORPORATION (US) | 1979-10-16 | — | — | US | disclosed |
| US-4045570-A | Heterocyclic S-imino-S-oxides | CIBA-GEIGY CORPORATION (US) | 1977-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108599-A1 | Heterocyclic Tetracyclic Tetrahydrofuran Derivatives As 5Ht2 Inhibitors In The Treatment Of Cns Disorders | HTR2C, HTR2A, TPH2 | ALDH1A1 580/4885HPGD 620/4885KDM4E 4647/4885 |
| US-20110144094-A1 | HETEROCYCLIC TETRACYCLIC TETRAHYDROFURAN DERIVATIVES | HTR2C, HTR2A, HTR5A | ALDH1A1 346/4885HPGD 444/4885KDM4E 4710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.